



Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

October 17, 2019

- *Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials*
- *Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs*

NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit. In one of these sessions, Ian Taylor, Ph.D., Chief Scientific Officer at Arvinas, will share an update on the company's PROTAC[®] protein degrader platform, including initial safety, tolerability, and pharmacokinetic data from Arvinas' ongoing Phase 1 clinical trials of ARV-110 and ARV-471.

Dr. Taylor's presentation is October 23 and is one of three that Arvinas will participate in at the conference, which is being held October 22-24 at the Hilton Boston Logan Airport in Boston, MA. On October 24, Angela Cacace, Ph.D., VP of Neuroscience and Platform Biology at Arvinas, will share recent data from Arvinas' preclinical neurodegeneration programs targeting tau and alpha-synuclein. Also, on October 24, Randy Teel, Ph.D., VP of Corporate Development, will participate in a panel discussion on the field of targeted protein degradation.

Arvinas Presentations at the 2nd Targeted Protein Degradation Summit

- *Moving PROTAC[®] Protein Degraders from the Laboratory to the Clinic*
 - Presenter: Ian Taylor, Ph.D., CSO
 - Date and Time: October 23 – 11:30 AM
- *Keynote Plenary: Accelerating Emerging Protein Degraders into the Clinic: Industry Leaders Panel Discussion*
 - Panelist: Randy Teel, Ph.D., VP, Corporate Development
 - Date and Time: October 24 – 9:30 AM
- *Discovery of Brain Penetrant PROTAC[®] Degradable Molecules that Target Pathologic Tau Protein Species*
 - Presenter: Angela Cacace, Ph.D., VP, Neuroscience and Platform Biology
 - Date and Time: October 24 – 11:30 AM

About Arvinas

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC[®] targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of patients with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with ER+/HER2- locally advanced or metastatic breast cancer. For more information, visit www.arvinas.com.

About ARV-110

ARV-110 is an orally-bioavailable PROTAC[®] protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). Arvinas' Phase 1 trial of ARV-110 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.

ARV-110 has demonstrated activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. Arvinas believes the differentiated pharmacology of ARV-110, including its iterative mechanism of action, has the potential to translate into meaningful clinical benefit for patients.

About ARV-471

ARV-471 is a PROTAC[®] protein degrader designed to specifically target and degrade the estrogen receptor (ER). Arvinas' Phase 1 trial of ARV-471 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.

In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity as a single agent and in combination with a CDK4/6 inhibitor when compared to a standard of care agent, fulvestrant (as a single agent and in combination with a CDK4/6 inhibitor). Arvinas believes the differentiated pharmacology of ARV-471, including its iterative mechanism of action, has the potential to translate into meaningful clinical benefit for patients.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, our scheduled participation at the 2nd Targeted Protein Degradation Conference, including the presentation of initial data from our clinical trials for ARV-110 and ARV-471, and the potential advantages and therapeutic potential of our

product candidates. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct Phase 1 clinical trials for ARV-110 and ARV-471, complete other clinical trials for our product candidates on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline and other important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

Contacts for Arvinas

Investor Relations

Will O'Connor, Stern Investor Relations

ir@arvinas.com

Media

Cory Tromblee, ScientPR

pr@arvinas.com



Source: Arvinas Inc.